Polygenic hazard score to guide screening for aggressive prostate cancer: Development and validation in large scale cohorts

BMJ (Online)

Volumn 360, Issue , 2018, Pages

  Seibert, Tyler M ^a,b   Fan, Chun Chieh ^a,c   Wang, Yunpeng ^d   Zuber, Verena ^d,e   Karunamuni, Roshan ^a,b   Parsons, J Kellogg ^f   Eeles, Rosalind A ^g,h   Easton, Douglas F ⁱ   Kote Jarai, Zsofia ^g   Al Olama, Ali Amin ^i,j   Garcia, Sara Benlloch ⁱ   Muir, Kenneth ^k,l   Grönberg, Henrik ^m   Wiklund, Fredrik ^m   Aly, Markus ^m,n,o   Schleutker, Johanna ^p,q,r   Sipeky, Csilla ^p,q   Tammela, Teuvo L J ^s   Nordestgaard, Børge G ^t,u   Nielsen, Sune F ^t,u   Weischer, Maren ^u   Bisbjerg, Rasmus ^v   Røder, M Andreas ^w   Iversen, Peter ^t,w   Key, Tim J ^x   Travis, Ruth C ^x   Neal, David E ^x,y   Donovan, Jenny L ^z   Hamdy, Freddie C ^x   Pharoah, Paul ⁱ   Pashayan, Nora ^i,aa   Khaw, Kay Tee ^j   Maier, Christiane ^ab   Vogel, Walther ^ab   Luedeke, Manuel ^ab   Herkommer, Kathleen ^ac   Kibel, Adam S ^ad   Cybulski, Cezary ^ae   Wokolorczyk, Dominika ^ae   Kluzniak, Wojciech ^ae   Cannon Albright, Lisa ^af,ag   Brenner, Hermann ^ah   Cuk, Katarina ^ah   Saum, Kai Uwe ^ah   Park, Jong Y ^ai   Sellers, Thomas A ^ai   Slavov, Chavdar ^aj   Kaneva, Radka ^ak   Mitev, Vanio ^ak   Batra, Jyotsna ^al   Clements, Judith A ^al   Spurdle, Amanda ^al,am   Teixeira, Manuel R ^an,ao   Paulo, Paula ^an   Maia, Sofia ^an   Pandha, Hardev ^ap   Michael, Agnieszka ^ap   Kierzek, Andrzej ^ap   Karow, David S ^a,aq   Mills, Ian G ^d,x,ar   Andreassen, Ole A ^d   Dale, Anders M ^a,aq,as   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e MRC BIOSTATISTICS UNIT   (United Kingdom)

^f UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^g INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^h INSTITUTE OF CANCER RESEARCH   (United Kingdom)

ⁱ UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k UNIVERSITY OF MANCHESTER   (United Kingdom)

^l UNIVERSITY OF WARWICK   (United Kingdom)

^m KAROLINSKA INSTITUTE   (Sweden)

ⁿ Turku University Hospital ^*  (Sweden)

^o KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^p UNIVERSITY OF TURKU   (Finland)

^q TURKU UNIVERSITY HOSPITAL   (Finland)

^r TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^s TAMPERE UNIVERSITY HOSPITAL   (Finland)

^t UNIVERSITY OF COPENHAGEN   (Denmark)

^u UNIVERSITY OF COPENHAGEN   (Denmark)

^v GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^w Mental Health Center Glostrup   (Denmark)

^x UNIVERSITY OF OXFORD   (United Kingdom)

^y UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^z UNIVERSITY OF BRISTOL   (United Kingdom)

^aa UNIVERSITY COLLEGE LONDON   (United Kingdom)

^ab UNIVERSITY HOSPITAL ULM   (Germany)

^ac TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^ad BRIGHAM AND WOMEN S HOSPITAL   (United States)

^ae POMERANIAN MEDICAL UNIVERSITY   (Poland)

^af UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^ag DEPARTMENT OF VETERANS AFFAIRS   (United States)

^ah GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^ai H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^aj UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

^ak MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^al QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^am QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^an PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^ao UNIVERSITY OF PORTO   (Portugal)

^ap UNIVERSITY OF SURREY   (United Kingdom)

^aq UNIVERSITY OF CALIFORNIA   (United States)

^ar QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^as UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; AGGRESSIVE PROSTATE CANCER; ARTICLE; CANCER EPIDEMIOLOGY; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DISTANT METASTASIS; FAMILY HISTORY; GENETIC ANALYSIS; GENETIC RISK; GENETIC SCREENING; GENOTYPE; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; ONSET AGE; POLYGENIC HAZARD SCORE; PRIORITY JOURNAL; PROSTATE CANCER; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; VALIDATION STUDY; BLOOD; CAUCASIAN; COMPARATIVE STUDY; DISEASE FREE SURVIVAL; EARLY CANCER DIAGNOSIS; GENETICS; MIDDLE AGED; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PROCEDURES; PROSTATE TUMOR; RISK ASSESSMENT; SURVIVAL ANALYSIS;

AGE OF ONSET; AGED; COHORT STUDIES; DISEASE-FREE SURVIVAL; EARLY DETECTION OF CANCER; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENOTYPE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POLYMORPHISM, SINGLE NUCLEOTIDE; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; SURVIVAL ANALYSIS;

EID: 85040518909     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j5757     Document Type: Article

References (36)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108. doi:10.3322/caac.21262
2. Schröder FH, Hugosson J, Roobol MJ, ERSPC Investigators. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-35. doi:10.1016/S0140-6736(14)60525-0
3. Wolf AMD, Wender RC, Etzioni RB, American Cancer Society Prostate Cancer Advisory Committee. American Cancer Society guideline for the early detection of prostate cancer: Update 2010. CA Cancer J Clin 2010;60:70-98. doi:10.3322/caac.20066
4. Horwich A, Hugosson J, de Reijke T, Wiegel T, Fizazi K, Kataja V, Panel Members, European Society for Medical Oncology. Prostate cancer: ESMO Consensus Conference Guidelines 2012. Ann Oncol 2013;24:1141-62. doi:10.1093/annonc/mds624
5. Qaseem A, Barry MJ, Denberg TD, Owens DK, Shekelle P, Clinical Guidelines Committee of the American College of Physicians. Screening for prostate cancer: A guidance statement from the Clinical Guidelines Committee of the American College of Physicians. Ann Intern Med 2013;158:761-9. doi:10.7326/0003-4819-158-10-201305210-00633
6. Eeles RA, Olama AAA, Benlloch S, COGS-Cancer Research UK GWAS-ELLIPSE (part of GAME-ON) Initiative, Australian Prostate Cancer Bioresource UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT (Prostate testing for cancer and Treatment) Study Collaborators, PRACTICAL (Prostate Cancer Association Group to Investigate Cancer-Associated Alterations in the Genome) Consortium. Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet 2013;45:385-91, e1-2. doi:10.1038/ng.2560
7. Goh CL, Schumacher FR, Easton D. Genetic variants associated with predisposition to prostate cancer and potential clinical implications. J Intern Med 2012;271:353-65. doi:10.1111/j.1365-2796.2012.02511.x
8. Witte JS. Personalized prostate cancer screening: Improving PSA tests with genomic information. Sci Transl Med 2010;2:62ps55. doi:10.1126/scitranslmed.3001861
9. Chatterjee N, Shi J, Garciá-Closas M. Developing and evaluating polygenic risk prediction models for stratified disease prevention. Nat Rev Genet 2016;17:392-406. doi:10.1038/nrg.2016.27
10. Pharoah PDP, Antoniou AC, Easton DF, Ponder BAJ. Polygenes, risk prediction, and targeted prevention of breast cancer. N Engl J Med 2008;358:2796-803. doi:10.1056/NEJMsa0708739
11. Pashayan N, Duffy SW, Chowdhury S. Polygenic susceptibility to prostate and breast cancer: Implications for personalised screening. Br J Cancer 2011;104:1656-63. doi:10.1038/bjc.2011.118
12. Lane JA, Donovan JL, Davis M, ProtecT study group. Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: Study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. Lancet Oncol 2014;15:1109-18. doi:10.1016/S1470-2045(14)70361-4
13. Loeb S, Bjurlin MA, Nicholson J. Overdiagnosis and overtreatment of prostate cancer. Eur Urol 2014;65:1046-55. doi:10.1016/j. eururo.2013.12.062
14. Mohler JL, Armstrong AJ, Bahnson RR. Prostate Cancer, Version 1.2016. J Natl Compr Canc Netw 2016;14:19-30. doi:10.6004/jnccn.2016.0004
15. Desikan RS, Fan CC, Wang Y. Personalized genetic assessment of age associated Alzheimers disease risk: Development and validation of a polygenic hazard score. PLoS Med 2016;14:e1002289.doi. org/10.1371/journal.pmed.1002258
16. Eeles R, Goh C, Castro E. The genetic epidemiology of prostate cancer and its clinical implications. Nat Rev Urol 2014;11:18-31. doi:10.1038/nrurol.2013.266
17. Fleshner NE, Lucia MS, Egerdie B. Dutasteride in localised prostate cancer management: The REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012;379:1103-11. doi:10.1016/S0140-6736(11)61619-X
18. Hamdy FC, Donovan JL, Lane JA, ProtecT Study Group. 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. N Engl J Med 2016;375:1415-24. doi:10.1056/NEJMoa1606220
19. Pashayan N, Pharoah P, Neal DE. PSA-detected prostate cancer and the potential for dedifferentiation-estimating the proportion capable of progression. Int J Cancer 2011;128:1462-70. doi:10.1002/ijc.25471
20. Gastwirth JL. A General Definition of the Lorenz Curve. Econometrica 1971;39:1037-9doi:10.2307/1909675.
21. Vickers AJ, Cronin AM, Björk T. Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: Case-control study. BMJ 2010;341:c4521. doi:10.1136/bmj.c4521
22. Vickers AJ, Ulmert D, Sjoberg DD. Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: Case-control study. BMJ 2013;346:f2023. doi:10.1136/bmj.f2023
23. Amin Al Olama A, Benlloch S, Antoniou AC, UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology, UK ProtecT Study Collaborators, PRACTICAL Consortium. Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. Cancer Epidemiol Biomarkers Prev 2015;24:1121-9. doi:10.1158/1055-9965. EPI-14-0317
24. Pashayan N, Duffy SW, Neal DE. Implications of polygenic riskstratified screening for prostate cancer on overdiagnosis. Genet Med 2015;17:789-95. doi:10.1038/gim.2014.192
25. Mikropoulos C, Goh C, Leongamornlert D, Kote-Jarai Z, Eeles R. Translating genetic risk factors for prostate cancer to the clinic: 2013 and beyond. Future Oncol 2014;10:1679-94. doi:10.2217/fon.14.72
26. Thompson IM, Ankerst DP, Chi C. Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2006;98:529-34. doi:10.1093/jnci/djj131
27. Kranse R, Roobol M, Schröder FH. A graphical device to represent the outcomes of a logistic regression analysis. Prostate 2008;68: 1674-80. doi:10.1002/pros.20840
28. Kader AK, Sun J, Reck BH. Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: Findings from the REDUCE trial. Eur Urol 2012;62:953-61. doi:10.1016/j. eururo.2012.05.006
29. Lilja H, Ulmert D, Björk T. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6. doi:10.1200/JCO.2006.06.9351
30. Loeb S, Carter HB, Catalona WJ, Moul JW, Schroder FH. Baseline prostate-specific antigen testing at a young age. Eur Urol 2012;61: 1-7. doi:10.1016/j.eururo.2011.07.067
31. Preston MA, Batista JL, Wilson KM. Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer. J Clin Oncol 2016;34:2705-11. doi:10.1200/JCO.2016.66.7527
32. Carroll PR, Parsons JK, Andriole G. NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016. J Natl Compr Canc Netw 2016;14:509-19. doi:10.6004/jnccn.2016.0060
33. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin 2016;66:7-30. doi:10.3322/caac.21332
34. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011;61:212-36. doi:10.3322/caac.20121
35. Jemal A, Siegel R, Ward E. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-30. doi:10.3322/canjclin.56.2.106
36. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36. doi:10.3322/canjclin.51.1.15